TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05248373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution with same composition as for vaccine formulation except rAds
Study: NCT04988880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Expert Patient Program of Catalonia
Description: It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Expert Patient Program of Catalonia
Description: It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
Study: NCT05458401

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: No drug will be administered during this study.
Study: NCT05742256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 1.5mg/kg
Description: Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Study: NCT05188001

Intervention type: OTHER
Intervention: Not an Interventional Study
Description: Not an interventional Study
Study: NCT05652062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prizvalve® system
Description: Transcatheter valve-in-valve replacement
Study: NCT04788550

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated toothpaste
Description: Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluoride varnish (5% sodium fluoride)
Description: Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CPP-ACP plus crème group
Description: Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
Study: NCT04728321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104 lenvatinib
Description: Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 until disease progression or for a maximum of 24 months
Study: NCT05725317

Intervention type: DEVICE
Group type: OTHER
Intervention: LID220365 contact lens
Description: Investigational delefilcon A spherical contact lens made with a modified manufacturing process

Intervention type: DEVICE
Group type: OTHER
Intervention: LID220365 contact lens
Description: Investigational delefilcon A spherical contact lens made with a modified manufacturing process

Intervention type: DEVICE
Group type: OTHER
Intervention: LID006961 contact lens
Description: Commercially available delefilcon A spherical contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: LID006961 contact lens
Description: Commercially available delefilcon A spherical contact lens
Study: NCT05945433

Intervention type: DEVICE
Intervention: anovo™ Surgical System
Description: The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
Study: NCT05245344

Intervention type: PROCEDURE
Intervention: Peripheral blood withdrawal
Description: 25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.

Intervention type: PROCEDURE
Intervention: Peripheral blood withdrawal
Description: 25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.

Intervention type: PROCEDURE
Intervention: Peripheral blood withdrawal
Description: 25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
Study: NCT05775614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroTainer®
Description: Clinical effect of preventive treatment - catheter flushing with UroTainer®

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Clinical effect of preventive treatment - catheter flushing with saline solution
Study: NCT04514458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
Description: Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Study: NCT03674346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnoanalgesia group
Description: The running of a hypnosis session is protocolized and is based on three times:~* The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~* The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~* The time of return. It is time that allows the patient to regain his classic state of consciousness.

Intervention type: OTHER
Group type: OTHER
Intervention: Meopa Group
Description: The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study.
Study: NCT05646186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on microbiome analysis
Description: Personalized dietary intervention based on individual microbiome analysis

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-FODMAP diet
Description: Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
Study: NCT04988451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASL Services
Description: ASL specialist meets with participants and provides ASL instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASL Services
Description: ASL specialist meets with participants and provides ASL instruction
Study: NCT06064227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention
Description: In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization.
Study: NCT06179524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T-19 cell injection
Description: The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
Study: NCT05238233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: One drop will be given to participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Pilocarpine
Description: One drop will be given to participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride
Description: One drop will be given to participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tono pen AVIA
Description: Participant intraocular pressures measured

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG4 Gonio
Description: Participant iridocorneal angle measured

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reichert phoropter
Description: Participant screened for hyperopia \>+1 diopter
Study: NCT04887454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Once-Weekly HIIT
Description: Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrice-Weekly HIIT
Description: Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
Study: NCT06537219

Intervention type: OTHER
Intervention: Assessment
Description: Assessment of pain severity,pain thresold of the fascia, pain sensitivity

Intervention type: OTHER
Intervention: Assessment
Description: Assessment of pain severity,pain thresold of the fascia, pain sensitivity
Study: NCT05322616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK07
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Vehicle control
Study: NCT05197894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
Study: NCT05168696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality Glasses
Study: NCT04559516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
Study: NCT05601102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: danceSing Care
Description: - Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
Study: NCT06048822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pickleball
Description: Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pickleball
Description: Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
Study: NCT05350943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W
Study: NCT04504188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Monitor Enhanced Treatment Optimization
Description: Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
Study: NCT03935425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitMi Plus
Description: A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitMi Basic
Description: A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
Study: NCT05350943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.2mg. P.O, BID, continuously
Study: NCT06209567

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET Scans
Description: Participants will be injected intravenously with 68Ga-PSMA-11 via intravenous catheter. PET scans will first be interpreted without information on the results of other imaging modalities. Following the blinded read of the 68Ga-PSMA-11 PET scans, all recorded findings will be correlated with the results of CE CT and MR studies and 18F-FDG PET/CT or PET/MR performed as part of standard clinical care.
Study: NCT05734222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias
Description: 1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias
Description: 1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment.
Study: NCT06249932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Study: NCT05570955

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text reminder
Description: weekly text to remind use of drug